What is Oncopole?
Headquartered in Quebec, Oncopole functions as a specialized hub dedicated to the advancement of cancer research and development. The organization operates at the intersection of public and private interests, facilitating a collaborative environment where scientific breakthroughs are translated into viable clinical solutions. Its market position is defined by its ability to mobilize resources and expertise, effectively serving as a catalyst for high-impact oncology projects that require both financial backing and strategic guidance to navigate the complex biopharmaceutical landscape.
How much funding has Oncopole raised?
Oncopole has raised a total of $5.5M across 1 funding round:
Other Financing Round
$5.5M
Other Financing Round (2023): $5.5M with participation from Merck & Co, Pfizer, and GSK
Key Investors in Oncopole
Merck & Co
Founded in 1891 and headquartered in Rahway, NJ, Merck & Co., Inc. is a global healthcare company delivering innovative solutions through prescription medicines, biologic therapies, vaccines, and animal health products.
Pfizer
Pfizer Inc. is a global biopharmaceutical company dedicated to discovering, developing, manufacturing, and delivering innovative medicines and vaccines that improve health outcomes and enhance quality of life.
GSK
GSK plc is a British multinational pharmaceutical and biotechnology company that discovers, develops, manufactures, and delivers medicines and vaccines with a research and development focus on oncology, immunology, and infectious diseases.
What's next for Oncopole?
With this latest round of financing, Oncopole is poised to scale its operational capacity and expand its portfolio of research initiatives. The strategic focus will likely shift toward enhancing clinical trial infrastructure and fostering deeper partnerships with global pharmaceutical entities. By leveraging its unique position within the Quebec biotech sector, the organization aims to shorten the development lifecycle for novel therapeutics, ultimately improving patient outcomes and reinforcing its status as a premier destination for oncology-focused capital and collaborative research efforts.
See full Oncopole company page
